Timothy Blackwell, MD
Vanderbilt University, B.S.
University of Alabama, M.D.
Internal Medicine, Pulmonary Diseases, Critical Care Medicine
Lisa Lancaster, MD
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University Medical Center
Method of Participation
Participants should read the CME/CE information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.
The online post-test and evaluation can be accessed at: https://tinyurl.com/IPFVideoConsult17
Inquiries may be directed to Global Academy for Medical Education at email@example.com or (973) 290-8225.
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the interstitial pneumonias, accounting for as many as 40,000 deaths in the United States annually. IPF is characterized by insidious onset and progressive decline in lung function, leading to death usually within four years of diagnosis. No cure is available, but two recently approved drugs, nintedanib and pirfenidone, have been found to slow the decline in lung function. In 2015 an international coalition of societies, including the American Thoracic Society (ATS), updated its guideline for the management of IPF. The guideline now indicates that certain therapies previously used for IPF are in fact harmful and should no longer be used. Clinicians need education about the revised strategies now recommended in guidelines for management of patients with IPF and should be able to design effective treatment while managing comorbidities (such as GERD) and addressing the common adverse effects of therapy.
- Discuss key changes in current guidelines for treatment of idiopathic pulmonary fibrosis (IPF)
- Design a therapeutic strategy for IPF incorporating current drug treatment recommendations
- Develop evidence-based approaches for managing common comorbidities of IPF and adverse events associated with its treatment
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy for
Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for .40 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Off-Label/Investigational Use Disclosure
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
Lisa Lancaster, MD: Consultant: Genentech, Hoffman-LaRoche, Boehringer-Ingelheim, and Whole Blood Therapeutics. Speaker’s Bureau: Genentech and Boehringer-Ingelheim. Grant/Research Support: Celgene, GBT Pharma, Hoffman-LaRoche.
Timothy Blackwell, MD: Has no conflicts of interest to report.
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The DKBmed planners and managers have nothing to disclose.
Global Academy for Medical Education Staff: Sylvia H. Reitman, MBA, DipEd; Mike LoPresti; Shirley V. Jones, MBA; and Ron Schaumburg hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Technical Questions
Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email firstname.lastname@example.org.
Copyright © 2016 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein